nodes	percent_of_prediction	percent_of_DWPC	metapath
Zonisamide—AOX1—Methotrexate—lymphatic system cancer	0.166	0.484	CbGbCtD
Zonisamide—CYP2C19—Teniposide—lymphatic system cancer	0.0695	0.203	CbGbCtD
Zonisamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0341	0.0995	CbGbCtD
Zonisamide—CYP3A4—Teniposide—lymphatic system cancer	0.0336	0.098	CbGbCtD
Zonisamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0235	0.0685	CbGbCtD
Zonisamide—CYP3A4—Vincristine—lymphatic system cancer	0.0162	0.0472	CbGbCtD
Zonisamide—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000955	0.00145	CcSEcCtD
Zonisamide—Alopecia—Carmustine—lymphatic system cancer	0.000947	0.00144	CcSEcCtD
Zonisamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.000941	0.00143	CcSEcCtD
Zonisamide—Mental disorder—Carmustine—lymphatic system cancer	0.000939	0.00143	CcSEcCtD
Zonisamide—Malnutrition—Carmustine—lymphatic system cancer	0.000933	0.00142	CcSEcCtD
Zonisamide—Cough—Bleomycin—lymphatic system cancer	0.000933	0.00142	CcSEcCtD
Zonisamide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000928	0.00141	CcSEcCtD
Zonisamide—Diarrhoea—Teniposide—lymphatic system cancer	0.000927	0.00141	CcSEcCtD
Zonisamide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000922	0.0014	CcSEcCtD
Zonisamide—Chest pain—Bleomycin—lymphatic system cancer	0.00091	0.00139	CcSEcCtD
Zonisamide—Myalgia—Bleomycin—lymphatic system cancer	0.00091	0.00139	CcSEcCtD
Zonisamide—Alopecia—Vincristine—lymphatic system cancer	0.000904	0.00138	CcSEcCtD
Zonisamide—Coma—Methotrexate—lymphatic system cancer	0.000904	0.00138	CcSEcCtD
Zonisamide—Discomfort—Bleomycin—lymphatic system cancer	0.000899	0.00137	CcSEcCtD
Zonisamide—Mental disorder—Vincristine—lymphatic system cancer	0.000897	0.00136	CcSEcCtD
Zonisamide—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000894	0.00136	CcSEcCtD
Zonisamide—Ecchymosis—Methotrexate—lymphatic system cancer	0.000894	0.00136	CcSEcCtD
Zonisamide—Urine output increased—Methotrexate—lymphatic system cancer	0.000894	0.00136	CcSEcCtD
Zonisamide—Bladder pain—Methotrexate—lymphatic system cancer	0.000894	0.00136	CcSEcCtD
Zonisamide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000885	0.00135	CcSEcCtD
Zonisamide—Alopecia—Mitoxantrone—lymphatic system cancer	0.000881	0.00134	CcSEcCtD
Zonisamide—Confusional state—Bleomycin—lymphatic system cancer	0.00088	0.00134	CcSEcCtD
Zonisamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000877	0.00133	CcSEcCtD
Zonisamide—Tremor—Carmustine—lymphatic system cancer	0.000874	0.00133	CcSEcCtD
Zonisamide—Oedema—Bleomycin—lymphatic system cancer	0.000873	0.00133	CcSEcCtD
Zonisamide—Infection—Bleomycin—lymphatic system cancer	0.000867	0.00132	CcSEcCtD
Zonisamide—Anaemia—Carmustine—lymphatic system cancer	0.000863	0.00131	CcSEcCtD
Zonisamide—Vomiting—Teniposide—lymphatic system cancer	0.000861	0.00131	CcSEcCtD
Zonisamide—Agitation—Carmustine—lymphatic system cancer	0.000858	0.00131	CcSEcCtD
Zonisamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000854	0.0013	CcSEcCtD
Zonisamide—Asthenia—Fludarabine—lymphatic system cancer	0.000854	0.0013	CcSEcCtD
Zonisamide—Rash—Teniposide—lymphatic system cancer	0.000854	0.0013	CcSEcCtD
Zonisamide—Dermatitis—Teniposide—lymphatic system cancer	0.000853	0.0013	CcSEcCtD
Zonisamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00085	0.00129	CcSEcCtD
Zonisamide—Headache—Teniposide—lymphatic system cancer	0.000848	0.00129	CcSEcCtD
Zonisamide—Pruritus—Fludarabine—lymphatic system cancer	0.000842	0.00128	CcSEcCtD
Zonisamide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000841	0.00128	CcSEcCtD
Zonisamide—Leukopenia—Carmustine—lymphatic system cancer	0.000835	0.00127	CcSEcCtD
Zonisamide—Anorexia—Bleomycin—lymphatic system cancer	0.000832	0.00127	CcSEcCtD
Zonisamide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000829	0.00126	CcSEcCtD
Zonisamide—Anaemia—Vincristine—lymphatic system cancer	0.000823	0.00125	CcSEcCtD
Zonisamide—Agitation—Vincristine—lymphatic system cancer	0.000819	0.00125	CcSEcCtD
Zonisamide—Polyuria—Methotrexate—lymphatic system cancer	0.000818	0.00124	CcSEcCtD
Zonisamide—Hypotension—Bleomycin—lymphatic system cancer	0.000815	0.00124	CcSEcCtD
Zonisamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000814	0.00124	CcSEcCtD
Zonisamide—Convulsion—Carmustine—lymphatic system cancer	0.000809	0.00123	CcSEcCtD
Zonisamide—Hypertension—Carmustine—lymphatic system cancer	0.000806	0.00123	CcSEcCtD
Zonisamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000805	0.00123	CcSEcCtD
Zonisamide—Nausea—Teniposide—lymphatic system cancer	0.000804	0.00122	CcSEcCtD
Zonisamide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000802	0.00122	CcSEcCtD
Zonisamide—Vertigo—Vincristine—lymphatic system cancer	0.0008	0.00122	CcSEcCtD
Zonisamide—Leukopenia—Vincristine—lymphatic system cancer	0.000798	0.00121	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000795	0.00121	CcSEcCtD
Zonisamide—Chest pain—Carmustine—lymphatic system cancer	0.000795	0.00121	CcSEcCtD
Zonisamide—Myalgia—Carmustine—lymphatic system cancer	0.000795	0.00121	CcSEcCtD
Zonisamide—Anxiety—Carmustine—lymphatic system cancer	0.000792	0.00121	CcSEcCtD
Zonisamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000784	0.00119	CcSEcCtD
Zonisamide—Malaise—Mitoxantrone—lymphatic system cancer	0.000782	0.00119	CcSEcCtD
Zonisamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.000778	0.00118	CcSEcCtD
Zonisamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000777	0.00118	CcSEcCtD
Zonisamide—Convulsion—Vincristine—lymphatic system cancer	0.000772	0.00118	CcSEcCtD
Zonisamide—Hypertension—Vincristine—lymphatic system cancer	0.000769	0.00117	CcSEcCtD
Zonisamide—Confusional state—Carmustine—lymphatic system cancer	0.000768	0.00117	CcSEcCtD
Zonisamide—Oedema—Carmustine—lymphatic system cancer	0.000762	0.00116	CcSEcCtD
Zonisamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000759	0.00115	CcSEcCtD
Zonisamide—Myalgia—Vincristine—lymphatic system cancer	0.000759	0.00115	CcSEcCtD
Zonisamide—Cough—Mitoxantrone—lymphatic system cancer	0.000757	0.00115	CcSEcCtD
Zonisamide—Infection—Carmustine—lymphatic system cancer	0.000757	0.00115	CcSEcCtD
Zonisamide—Vomiting—Fludarabine—lymphatic system cancer	0.000757	0.00115	CcSEcCtD
Zonisamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.000752	0.00114	CcSEcCtD
Zonisamide—Rash—Fludarabine—lymphatic system cancer	0.00075	0.00114	CcSEcCtD
Zonisamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00075	0.00114	CcSEcCtD
Zonisamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000749	0.00114	CcSEcCtD
Zonisamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000746	0.00114	CcSEcCtD
Zonisamide—Headache—Fludarabine—lymphatic system cancer	0.000746	0.00113	CcSEcCtD
Zonisamide—Tachycardia—Carmustine—lymphatic system cancer	0.000743	0.00113	CcSEcCtD
Zonisamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000739	0.00112	CcSEcCtD
Zonisamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000739	0.00112	CcSEcCtD
Zonisamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000739	0.00112	CcSEcCtD
Zonisamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.000736	0.00112	CcSEcCtD
Zonisamide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000733	0.00112	CcSEcCtD
Zonisamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00073	0.00111	CcSEcCtD
Zonisamide—Oedema—Vincristine—lymphatic system cancer	0.000727	0.00111	CcSEcCtD
Zonisamide—Anorexia—Carmustine—lymphatic system cancer	0.000726	0.00111	CcSEcCtD
Zonisamide—Infection—Vincristine—lymphatic system cancer	0.000722	0.0011	CcSEcCtD
Zonisamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000719	0.00109	CcSEcCtD
Zonisamide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000718	0.00109	CcSEcCtD
Zonisamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000714	0.00109	CcSEcCtD
Zonisamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000713	0.00109	CcSEcCtD
Zonisamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000712	0.00108	CcSEcCtD
Zonisamide—Hypotension—Carmustine—lymphatic system cancer	0.000712	0.00108	CcSEcCtD
Zonisamide—Oedema—Mitoxantrone—lymphatic system cancer	0.000708	0.00108	CcSEcCtD
Zonisamide—Nausea—Fludarabine—lymphatic system cancer	0.000707	0.00108	CcSEcCtD
Zonisamide—Infection—Mitoxantrone—lymphatic system cancer	0.000704	0.00107	CcSEcCtD
Zonisamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000703	0.00107	CcSEcCtD
Zonisamide—Shock—Mitoxantrone—lymphatic system cancer	0.000697	0.00106	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000694	0.00106	CcSEcCtD
Zonisamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000693	0.00106	CcSEcCtD
Zonisamide—Urticaria—Bleomycin—lymphatic system cancer	0.000693	0.00106	CcSEcCtD
Zonisamide—Anorexia—Vincristine—lymphatic system cancer	0.000693	0.00106	CcSEcCtD
Zonisamide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000691	0.00105	CcSEcCtD
Zonisamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00069	0.00105	CcSEcCtD
Zonisamide—Insomnia—Carmustine—lymphatic system cancer	0.000689	0.00105	CcSEcCtD
Zonisamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000688	0.00105	CcSEcCtD
Zonisamide—Irritability—Methotrexate—lymphatic system cancer	0.000685	0.00104	CcSEcCtD
Zonisamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000685	0.00104	CcSEcCtD
Zonisamide—Paraesthesia—Carmustine—lymphatic system cancer	0.000684	0.00104	CcSEcCtD
Zonisamide—Mood swings—Methotrexate—lymphatic system cancer	0.00068	0.00104	CcSEcCtD
Zonisamide—Hypotension—Vincristine—lymphatic system cancer	0.000679	0.00103	CcSEcCtD
Zonisamide—Dyspnoea—Carmustine—lymphatic system cancer	0.000679	0.00103	CcSEcCtD
Zonisamide—Somnolence—Carmustine—lymphatic system cancer	0.000677	0.00103	CcSEcCtD
Zonisamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000675	0.00103	CcSEcCtD
Zonisamide—Ataxia—Methotrexate—lymphatic system cancer	0.000675	0.00103	CcSEcCtD
Zonisamide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000663	0.00101	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000662	0.00101	CcSEcCtD
Zonisamide—Decreased appetite—Carmustine—lymphatic system cancer	0.000662	0.00101	CcSEcCtD
Zonisamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000662	0.00101	CcSEcCtD
Zonisamide—Insomnia—Vincristine—lymphatic system cancer	0.000658	0.001	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000658	0.001	CcSEcCtD
Zonisamide—Paraesthesia—Vincristine—lymphatic system cancer	0.000653	0.000994	CcSEcCtD
Zonisamide—Constipation—Carmustine—lymphatic system cancer	0.000651	0.000991	CcSEcCtD
Zonisamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000646	0.000984	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000645	0.000982	CcSEcCtD
Zonisamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000643	0.000979	CcSEcCtD
Zonisamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000636	0.000968	CcSEcCtD
Zonisamide—Decreased appetite—Vincristine—lymphatic system cancer	0.000632	0.000962	CcSEcCtD
Zonisamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000631	0.000961	CcSEcCtD
Zonisamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00063	0.000958	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000628	0.000956	CcSEcCtD
Zonisamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000628	0.000955	CcSEcCtD
Zonisamide—Fatigue—Vincristine—lymphatic system cancer	0.000627	0.000954	CcSEcCtD
Zonisamide—Asthenia—Bleomycin—lymphatic system cancer	0.000626	0.000953	CcSEcCtD
Zonisamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000623	0.000949	CcSEcCtD
Zonisamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000623	0.000948	CcSEcCtD
Zonisamide—Constipation—Vincristine—lymphatic system cancer	0.000622	0.000946	CcSEcCtD
Zonisamide—Pruritus—Bleomycin—lymphatic system cancer	0.000617	0.00094	CcSEcCtD
Zonisamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000616	0.000937	CcSEcCtD
Zonisamide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000614	0.000935	CcSEcCtD
Zonisamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000611	0.000929	CcSEcCtD
Zonisamide—Pancreatitis—Methotrexate—lymphatic system cancer	0.000608	0.000926	CcSEcCtD
Zonisamide—Constipation—Mitoxantrone—lymphatic system cancer	0.000606	0.000922	CcSEcCtD
Zonisamide—Body temperature increased—Carmustine—lymphatic system cancer	0.000602	0.000917	CcSEcCtD
Zonisamide—Abdominal pain—Carmustine—lymphatic system cancer	0.000602	0.000917	CcSEcCtD
Zonisamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000595	0.000905	CcSEcCtD
Zonisamide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000589	0.000897	CcSEcCtD
Zonisamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000584	0.000888	CcSEcCtD
Zonisamide—Dysuria—Methotrexate—lymphatic system cancer	0.00058	0.000883	CcSEcCtD
Zonisamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000579	0.000881	CcSEcCtD
Zonisamide—Body temperature increased—Vincristine—lymphatic system cancer	0.000575	0.000875	CcSEcCtD
Zonisamide—Abdominal pain—Vincristine—lymphatic system cancer	0.000575	0.000875	CcSEcCtD
Zonisamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000571	0.00087	CcSEcCtD
Zonisamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000563	0.000856	CcSEcCtD
Zonisamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000561	0.000854	CcSEcCtD
Zonisamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00056	0.000852	CcSEcCtD
Zonisamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00056	0.000852	CcSEcCtD
Zonisamide—Pneumonia—Methotrexate—lymphatic system cancer	0.000556	0.000847	CcSEcCtD
Zonisamide—Vomiting—Bleomycin—lymphatic system cancer	0.000555	0.000845	CcSEcCtD
Zonisamide—Depression—Methotrexate—lymphatic system cancer	0.000552	0.00084	CcSEcCtD
Zonisamide—Rash—Bleomycin—lymphatic system cancer	0.00055	0.000838	CcSEcCtD
Zonisamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00055	0.000837	CcSEcCtD
Zonisamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000548	0.000835	CcSEcCtD
Zonisamide—Asthenia—Carmustine—lymphatic system cancer	0.000547	0.000832	CcSEcCtD
Zonisamide—Renal failure—Methotrexate—lymphatic system cancer	0.000544	0.000828	CcSEcCtD
Zonisamide—Stomatitis—Methotrexate—lymphatic system cancer	0.000539	0.000821	CcSEcCtD
Zonisamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000538	0.000818	CcSEcCtD
Zonisamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000536	0.000815	CcSEcCtD
Zonisamide—Sweating—Methotrexate—lymphatic system cancer	0.00053	0.000807	CcSEcCtD
Zonisamide—Haematuria—Methotrexate—lymphatic system cancer	0.000527	0.000803	CcSEcCtD
Zonisamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000523	0.000796	CcSEcCtD
Zonisamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000522	0.000794	CcSEcCtD
Zonisamide—Asthenia—Vincristine—lymphatic system cancer	0.000522	0.000794	CcSEcCtD
Zonisamide—Diarrhoea—Carmustine—lymphatic system cancer	0.000521	0.000793	CcSEcCtD
Zonisamide—Nausea—Bleomycin—lymphatic system cancer	0.000518	0.000789	CcSEcCtD
Zonisamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000516	0.000786	CcSEcCtD
Zonisamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000508	0.000773	CcSEcCtD
Zonisamide—Dizziness—Carmustine—lymphatic system cancer	0.000504	0.000767	CcSEcCtD
Zonisamide—Diarrhoea—Vincristine—lymphatic system cancer	0.000498	0.000757	CcSEcCtD
Zonisamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000493	0.00075	CcSEcCtD
Zonisamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00049	0.000747	CcSEcCtD
Zonisamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000487	0.000741	CcSEcCtD
Zonisamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000485	0.000738	CcSEcCtD
Zonisamide—Vomiting—Carmustine—lymphatic system cancer	0.000484	0.000737	CcSEcCtD
Zonisamide—Dizziness—Vincristine—lymphatic system cancer	0.000481	0.000732	CcSEcCtD
Zonisamide—Rash—Carmustine—lymphatic system cancer	0.00048	0.000731	CcSEcCtD
Zonisamide—Dermatitis—Carmustine—lymphatic system cancer	0.00048	0.00073	CcSEcCtD
Zonisamide—Headache—Carmustine—lymphatic system cancer	0.000477	0.000726	CcSEcCtD
Zonisamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00047	0.000715	CcSEcCtD
Zonisamide—Eye disorder—Methotrexate—lymphatic system cancer	0.000464	0.000706	CcSEcCtD
Zonisamide—Tinnitus—Methotrexate—lymphatic system cancer	0.000463	0.000705	CcSEcCtD
Zonisamide—Vomiting—Vincristine—lymphatic system cancer	0.000462	0.000704	CcSEcCtD
Zonisamide—Rash—Vincristine—lymphatic system cancer	0.000458	0.000698	CcSEcCtD
Zonisamide—Dermatitis—Vincristine—lymphatic system cancer	0.000458	0.000697	CcSEcCtD
Zonisamide—Headache—Vincristine—lymphatic system cancer	0.000456	0.000693	CcSEcCtD
Zonisamide—Nausea—Carmustine—lymphatic system cancer	0.000452	0.000689	CcSEcCtD
Zonisamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00045	0.000685	CcSEcCtD
Zonisamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000449	0.000683	CcSEcCtD
Zonisamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000448	0.000681	CcSEcCtD
Zonisamide—Rash—Mitoxantrone—lymphatic system cancer	0.000447	0.00068	CcSEcCtD
Zonisamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000446	0.000679	CcSEcCtD
Zonisamide—Headache—Mitoxantrone—lymphatic system cancer	0.000444	0.000675	CcSEcCtD
Zonisamide—Alopecia—Methotrexate—lymphatic system cancer	0.000439	0.000668	CcSEcCtD
Zonisamide—Mental disorder—Methotrexate—lymphatic system cancer	0.000435	0.000662	CcSEcCtD
Zonisamide—Malnutrition—Methotrexate—lymphatic system cancer	0.000432	0.000658	CcSEcCtD
Zonisamide—Nausea—Vincristine—lymphatic system cancer	0.000432	0.000657	CcSEcCtD
Zonisamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000423	0.000644	CcSEcCtD
Zonisamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000421	0.00064	CcSEcCtD
Zonisamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000401	0.000611	CcSEcCtD
Zonisamide—Anaemia—Methotrexate—lymphatic system cancer	0.0004	0.000608	CcSEcCtD
Zonisamide—Malaise—Methotrexate—lymphatic system cancer	0.00039	0.000593	CcSEcCtD
Zonisamide—Vertigo—Methotrexate—lymphatic system cancer	0.000388	0.000591	CcSEcCtD
Zonisamide—Leukopenia—Methotrexate—lymphatic system cancer	0.000387	0.000589	CcSEcCtD
Zonisamide—Cough—Methotrexate—lymphatic system cancer	0.000377	0.000574	CcSEcCtD
Zonisamide—Convulsion—Methotrexate—lymphatic system cancer	0.000375	0.00057	CcSEcCtD
Zonisamide—Arthralgia—Methotrexate—lymphatic system cancer	0.000368	0.00056	CcSEcCtD
Zonisamide—Myalgia—Methotrexate—lymphatic system cancer	0.000368	0.00056	CcSEcCtD
Zonisamide—Chest pain—Methotrexate—lymphatic system cancer	0.000368	0.00056	CcSEcCtD
Zonisamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000366	0.000556	CcSEcCtD
Zonisamide—Discomfort—Methotrexate—lymphatic system cancer	0.000364	0.000554	CcSEcCtD
Zonisamide—Confusional state—Methotrexate—lymphatic system cancer	0.000356	0.000542	CcSEcCtD
Zonisamide—Infection—Methotrexate—lymphatic system cancer	0.000351	0.000534	CcSEcCtD
Zonisamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000346	0.000527	CcSEcCtD
Zonisamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000345	0.000526	CcSEcCtD
Zonisamide—Skin disorder—Methotrexate—lymphatic system cancer	0.000343	0.000522	CcSEcCtD
Zonisamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000341	0.000519	CcSEcCtD
Zonisamide—Anorexia—Methotrexate—lymphatic system cancer	0.000336	0.000512	CcSEcCtD
Zonisamide—Hypotension—Methotrexate—lymphatic system cancer	0.00033	0.000502	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000321	0.000489	CcSEcCtD
Zonisamide—Insomnia—Methotrexate—lymphatic system cancer	0.000319	0.000486	CcSEcCtD
Zonisamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000317	0.000482	CcSEcCtD
Zonisamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000315	0.000479	CcSEcCtD
Zonisamide—Somnolence—Methotrexate—lymphatic system cancer	0.000314	0.000477	CcSEcCtD
Zonisamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000311	0.000473	CcSEcCtD
Zonisamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000307	0.000467	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000305	0.000464	CcSEcCtD
Zonisamide—Fatigue—Methotrexate—lymphatic system cancer	0.000304	0.000463	CcSEcCtD
Zonisamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000291	0.000443	CcSEcCtD
Zonisamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000289	0.000439	CcSEcCtD
Zonisamide—Urticaria—Methotrexate—lymphatic system cancer	0.00028	0.000427	CcSEcCtD
Zonisamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000279	0.000425	CcSEcCtD
Zonisamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000279	0.000425	CcSEcCtD
Zonisamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00026	0.000396	CcSEcCtD
Zonisamide—Asthenia—Methotrexate—lymphatic system cancer	0.000253	0.000385	CcSEcCtD
Zonisamide—Pruritus—Methotrexate—lymphatic system cancer	0.00025	0.00038	CcSEcCtD
Zonisamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000241	0.000367	CcSEcCtD
Zonisamide—Dizziness—Methotrexate—lymphatic system cancer	0.000233	0.000355	CcSEcCtD
Zonisamide—Vomiting—Methotrexate—lymphatic system cancer	0.000224	0.000341	CcSEcCtD
Zonisamide—Rash—Methotrexate—lymphatic system cancer	0.000222	0.000339	CcSEcCtD
Zonisamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000222	0.000338	CcSEcCtD
Zonisamide—Headache—Methotrexate—lymphatic system cancer	0.000221	0.000336	CcSEcCtD
Zonisamide—Nausea—Methotrexate—lymphatic system cancer	0.00021	0.000319	CcSEcCtD
